Data from the colorectal cancer cohort of the KRYSTAL-1 trial support the accelerated approval of adagrasib/cetuximab in KRAS G12C–mutated disease.
Approval Alert | Adagrasib/Cetuximab in KRAS G12C-Mutated Colorectal Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
3
Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma
4
What Were The Most Impactful GU Oncology Data From ESMO 2025?
5
